Current Status of Drug Clinical Trials for Head and Neck Cancer in Mainland China: An Analysis Based on the NMPA Database

The Great Medical Treasure Hunt: Why Head and Neck Cancer Needs More Heroes

Imagine the human body as a bustling, complex city. Sometimes, a group of cells decides to stop following the rules and starts building chaotic, unauthorized structures. We call these tumors. When these rogue builders set up shop in the "head and neck" district—covering everything from the mouth and throat to the voice box and salivary glands—it creates a serious traffic jam that can block breathing, eating, and speaking. This is head and neck cancer, a tough opponent that affects hundreds of thousands of people in China every year.

To fight this enemy, scientists act like detectives and engineers. They don't just guess what works; they run "clinical trials." Think of a clinical trial as a massive, carefully planned test drive for a new medicine. Before a drug can be sold to the public, it has to prove it's safe and effective in these tests, which involve real people volunteering to try the new treatment. In China, there is a giant digital "scoreboard" called the NMPA database where every single one of these test drives must be registered. This scoreboard is the ultimate source of truth for seeing which medicines are being tested, where, and how well the testing is going. The big question is: Are we testing enough new weapons for this specific type of cancer, and are we testing them in the smartest way possible?

The Map of the Medical Quest

A team of researchers decided to pull up a chair and study this giant scoreboard to see what's really happening with head and neck cancer drugs in mainland China. They looked at every single trial registered between September 2013 and December 2025. It was like scanning a library of 160 different medical adventure stories to see which ones were still being written, which had finished, and which had been cancelled.

The Plot Twist: We're Running, But Not Fast Enough
The researchers found that the number of new trials started growing slowly at first, but then took off like a rocket after 2018, peaking in 2021 with 26 new trials in a single year. By the end of 2025, there were 160 registered trials in total. While that sounds like a lot, the authors point out a sobering fact: head and neck cancer makes up about 3% to 6% of all cancers in China, yet these trials make up less than 0.5% of all drug trials registered on the platform. It's as if a city has a major problem with potholes in one specific neighborhood, but the construction crew is spending almost all their time fixing roads in other parts of town. The researchers suggest this means there is a "marked underinvestment" in finding cures for this specific area.

The Cast of Characters: Biologics and Targets
When looking at what kind of medicines are being tested, the story gets interesting. The vast majority—about 71.9%—are "biologics." You can think of these as high-tech, custom-made biological tools (like antibodies) rather than simple chemical pills. The most popular "targets" these drugs aim at are like locking onto specific weak spots on the cancer cells. The top targets are PD-1, EGFR, and PD-L1. These are the "VIPs" of the drug world right now.

However, the researchers noticed a huge missing piece of the puzzle: Zero trials were found for Traditional Chinese Medicine (TCM) or natural products. Even though China has a rich history of using herbs and natural remedies, no one has officially registered a clinical trial for these in head and neck cancer during this period. The authors suggest this might be because these medicines are hard to test under strict modern rules, or companies just aren't willing to invest in them yet.

The Stage and the Actors
Where are these trials happening? The map shows a heavy concentration in the "East." About half of all the trials are led by institutions in just three places: Shanghai, Guangdong, and Beijing. The top five hospitals alone are responsible for more than 70% of all the work. It's like all the best actors and directors are in one big city, while other regions are waiting in the wings.

There is also a gap in the types of hospitals leading the charge. Head and neck cancer often starts in the mouth, so you'd expect dentists and oral surgeons to be leading the way. But the data shows that only one stomatology (dental) hospital has ever led a drug trial for this cancer. Instead, general cancer centers and big hospitals are doing almost all the leading. The authors suggest that dental hospitals need to step up and build better teams to handle these complex drug tests.

The Rules of the Game: Safety and Design
The researchers also checked the "rulebooks" of these trials. They found that most trials (about 47.5%) are "single-arm," meaning everyone gets the new drug, and there's no control group to compare them against. While this is okay for early testing, the "gold standard" for proving a drug works is a randomized, double-blind trial (where some get the drug, some get a fake, and neither the patient nor the doctor knows who has which). Only about 17.5% of the trials used this gold-standard design.

Furthermore, safety is a mixed bag. While most trials (87.5%) bought insurance to protect the volunteers, only 18.1% had an independent committee to watch the data and stop the trial if things went wrong. The authors warn that without these safety nets, we might miss important risks or benefits.

The Final Verdict
So, what's the takeaway? The landscape of head and neck cancer drug trials in China has improved significantly over the last decade, with more trials starting and more domestic companies joining the fight. However, the authors argue that we are still in the "early exploration" phase. Most trials are still in the early stages (Phase I and II), with very few reaching the final, big tests (Phase III) that lead to new drugs hitting the market.

The paper suggests that to win this battle, we need to:

1. Invest more: Treat head and neck cancer with the same urgency as other major cancers.
2. Diversify: Don't just stick to the same few drug targets; look for new ones.
3. Explore the unknown: Finally give Traditional Chinese Medicine and natural products a fair shot in the lab.
4. Spread the wealth: Help hospitals outside of Shanghai and Beijing, and especially dental hospitals, get better at running these trials.

The researchers conclude that while the engine is running, the car needs a few more upgrades to get to the finish line where patients can actually use these new, life-saving medicines.